厄贝沙坦联合百令胶囊对原发性肾病综合征预后的影响

目的观察38例原发性系膜增生性肾小球肾炎肾病综合征的临床疗效。方法收集我科2002年1月至2007年4月收治的38例原发性肾病综合征病例,病理检查明确为系膜增生性肾小球肾炎后随机分为单纯治疗组（单用强的松治疗）和联合治疗组（在强的松基础上加用厄贝沙坦及百令胶囊）,检测治疗前、后各组SCr、BUN、血钾、血浆白蛋白、24小时尿蛋白定量的变化,明确治疗效果并长期随访,明确各组缓解后的复发率。结果治疗8周后,联合组治疗前、后24小时尿蛋白定量显著降低、血浆白蛋白明显升高（P〈0.05）,其肾病综合征缓解率明显优越于单纯治疗组（P〈0.05）,随访分析发现肾病综合征复发率显著低于单纯治疗组,远期预后明显提高。结论厄贝沙坦联合百令胶囊治疗原发性肾病综合征能更有效地提高疗效,降低复发,改善远期预后。

Effect of Irbesartan Combined with Bailing Capsule an Prognosis of Primary Nephrofic Syndrome

Objective To observe the effect of Irbesartan combined with Bailing capsule on outcom in Primary nephrotic syndrome.Methods 38 patients with Primary nephrotic syndrom were randomly divided into two groups：single-steroid treated group（SS group） and steroid combined with Irbesartan and Bailing treated group（SIB group）. Serum creatinine, BUN,Serum potassium,plasm albumin and 24-hour urine protein excretion were tested before and 8 weeks after therapy. All cases were followed up and remession rates and relaps rates were evaluated.Results Both in SS group and SIB group,24-hour urine protein excretion was significantly reduced,plasm albumin significantly increased（P〈0.05） after treatment with Irbesartan and bailing capsule.The remission rate in SIB group signifcantly higher than that in SS group. Comparing with SS group,the relapse rate in SIB group were significantly lower. Conclusion The therapy of steroid combined with Irbesartan and Bailing capsule can significantly improve the prognosis of Primary nephrotic syndrome.